Nobel Prize-winning technology may enable delivery of up to 12x the standard doxorubicin dose

Alex Morozov named chief medical officer at Pi Health

Alex Morozov was named the first chief medical officer of Pi Health, an oncology clinical trial and research technology company.

August 09, 2024

Vol.50 No.32

In Brief

The American Society for Cell Biology names 17 scientists as 2024 fellows

The American Society for Cell Biology is pleased to present its cohort of 17 fellows for 2024.

August 09, 2024

Vol.50 No.32

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

Language barriers hinder diverse recruitment to clinical trials

Underrepresentation of racial and ethnic minority populations in cancer clinical trials persists partly because translation and interpretation services and resources are unavailable or inadequate in the United States, according to a Children’s Oncology Group study led by Columbia University School of Nursing.

August 02, 2024

Vol.50 No.31

Regulatory News

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

In Brief

Lei Zheng named executive director of Mays Cancer Center

Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.

July 12, 2024

Vol.50 No.28

Nobel Prize-winning technology may enable delivery of up to 12x the standard doxorubicin dose

YOU MAY BE INTERESTED IN

Alex Morozov named chief medical officer at Pi Health

The American Society for Cell Biology names 17 scientists as 2024 fellows

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

Language barriers hinder diverse recruitment to clinical trials

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Lei Zheng named executive director of Mays Cancer Center

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

Nobel Prize-winning technology may enable delivery of up to 12x the standard doxorubicin dose

YOU MAY BE INTERESTED IN

Alex Morozov named chief medical officer at Pi Health

The American Society for Cell Biology names 17 scientists as 2024 fellows

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

Language barriers hinder diverse recruitment to clinical trials

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Lei Zheng named executive director of Mays Cancer Center

Can you spare 10 minutes to complete a survey?

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC